Research
Hormonal
Upper body subcutaneous fat is the primary source of excess free fatty acid (FFA) release in upper body obesity, contributing more to systemic FFA levels and metabolic risk than visceral fat itself.
When addressing upper body obesity, recognize that subcutaneous fat in the abdominal area is a major contributor to metabolic issues by releasing fatty acids into the bloodstream. Strategies to improve metabolic health should consider this specific fat depot's behavior.
StrongSupportsHIGH confidence
In upper body obesity and type 2 diabetes, the vast majority of excess FFA release during hyperinsulinemic conditions is from the upper body subcutaneous fat rather than visceral fat [39].
Why this rating
Based on cited primary research and the authors' own findings.
Source
Fat Depots, Free Fatty Acids, and Dyslipidemia
Jon O. Ebbert et al. · Nutrients · 2013
DOI 10.3390/nu5020498
narrative_reviewCited 349×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Excess visceral fat and upper body subcutaneous fat impair insulin-mediated suppression of free fatty acid (FFA) release, leading to elevated systemic FFA levels that drive hepatic VLDL-triglyceride overproduction and low HDL cholesterol, thereby increasing cardiovascular disease risk.Strong
- Elevated free fatty acid (FFA) delivery to the liver from visceral and upper body subcutaneous fat depots stimulates hepatic VLDL-triglyceride production, leading to hypertriglyceridemia and low HDL cholesterol, which are independent risk factors for cardiovascular disease.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →